REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
07/11/2026
Back to search
Official data from USPTO
HEPTARES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
HEPTARES
ST13
US500000086577541Class
1, 5, 42, 44
Filing
86577541
Registration
5239010
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
07/11/2026
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
03/26/2015
Registration date
07/11/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/02/2024
Last transaction
07/11/2026
Responsible office
United States Patent and Trademark Office
Status code
705
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
99
Owner location
TOKYO, JP
Examiner
HUNT, LEE
Law office
M60
Holders and representatives
Holders
NXERA PHARMA CO., LTD
SOSEI GROUP CORPORATION
Heptares Therapeutics Limited
Heptares Therapeutics Limited
Representatives
Rebecca Liebowitz VENABLE LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals and proteins used in researchfor chemistry and biological drug discoverylead identification and diagnostics; proteins including G-protein-coupled receptorstrans-membrane proteins and parts thereoffor use in pharmaceutical researchdrug discovery purposes
Class 5
Biological products for medical purposesg-protein-coupled receptorstransmembrane proteins and parts thereof for use in chemical and biological drug discoverylead identificationdiagnostics and therapeutic purposes; biological and chemical products for medical useproteinsG-protein-coupled receptorstransmembrane proteinsG-Proteinsantibodies and peptides and parts thereoffor therapeutic purposes; chemicalsproteins and parts thereof for use in medical diagnostics; none being dietetic substances adapted for medical use or food products
Class 42
Biotechnology testinggenetic testing for scientific research purposes; Biotechnology research; Biotechnology developmentdevelopment in the field of drug discovery and biopharmaceuticals; biotechnology advice; Biotechnology consultancy; Biotechnology informationproviding information on the subject of scientific research in the field of biotechnology; Pharmaceutical testing; pharmaceutical research; pharmaceutical development; pharmaceutical consultancy for non-medical purposes; Providing medical and scientific research information in the fields of pharmaceuticals; scientific testing and research in the pharmaceutical and biopharmaceutical fieldschemical and biological drug discovery services; providing scientific informationadviceconsultancy in the field of technologies related to proteinsincluding transmembrane proteins and G-proteinsG protein coupled receptorsparts thereof; bio-technologypharmaceutical and scientific testingresearchdevelopmentadviceconsultancy and information services; biological research; Research and development in the pharmaceutical and biopharmaceutical fieldstechnologies related to proteins and G protein coupled receptors; biology and chemistry servicesresearch and consulting in the field of chemistry and biology; pharmaceutical research serviceschemical and biological drug discovery services; research and development services for pharmaceutical lead identification; synthetic chemistry consultation services and research; research and development services in the creation of libraries or collections of biologicalschemicals and compounds; researchcreationdevelopment and provision of chemical and biological drug targets for non-medical screening purposes; researchanalysis and identification of compounds through automated screening processes research and development services relating to pharmaceutical research serviceschemical and biological drug discovery services
Class 44
Pharmaceutical advice; pharmaceutical consultancy for medical purposes; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; researchcreationdevelopment and provision of chemical and biological drug targets for medical screening purposes
Publications
History of USPTO decisions and trademark events.
50 publications found
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
07/04/2024
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
01/02/2024
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/02/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
01/02/2024
E815
TEAS SECTION 8 & 15 RECEIVED
07/10/2023
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
07/11/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/06/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/30/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/30/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
07/11/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/25/2017
PUBO
PUBLISHED FOR OPPOSITION
04/25/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/05/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/17/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/10/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/03/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/03/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/01/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
08/05/2016
GNRT
NON-FINAL ACTION E-MAILED
08/05/2016
CNRT
NON-FINAL ACTION WRITTEN
08/05/2016
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
07/07/2016
GNSF
SUBSEQUENT FINAL EMAILED
07/07/2016
CFRC
SUBSEQUENT FINAL REFUSAL WRITTEN
07/07/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/15/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/15/2016
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
06/15/2016
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
03/08/2016
GNFR
FINAL REFUSAL E-MAILED
03/08/2016
CNFR
FINAL REFUSAL WRITTEN
03/08/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/16/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/16/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/16/2016
GAUN
NOTIFICATION OF NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
01/20/2016
GAUD
NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
01/20/2016
NAUD
REPORT UNRESPONSIVE AMENDMENT - COMPLETED
01/20/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/20/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/20/2016
ALIE
ASSIGNED TO LIE
01/15/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/08/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/12/2015
GNRT
NON-FINAL ACTION E-MAILED
07/12/2015
CNRT
NON-FINAL ACTION WRITTEN
07/12/2015
DOCK
ASSIGNED TO EXAMINER
06/29/2015
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
06/05/2015
ALIE
ASSIGNED TO LIE
06/01/2015
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
05/27/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/04/2015
NWAP
NEW APPLICATION ENTERED
03/30/2015
Continuous trademark protection
Get notified about every new filing that threatens HEPTARES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.